Goode AP, Schwartz TA, Kraus VB, Huebner JL, George SZ, Cleveland RJ, Gracely R, Jimenez M, DeFrate LE, Chen J, Golightly YM, Jordan JM. Inflammatory, structural, and pain biochemical biomarkers may reflect radiographic disc space narrowing: The Johnston County Osteoarthritis Project. J Orthop Res. 2020 May;38(5):1027-37. doi: 10.1002/jor.24534
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Williams VSL, Soliman AM, Barrett AM, Klein KO. Review and evaluation of patient-centered psychosocial assessments for children with central precocious puberty or early puberty. J Pediatr Endocrinol Metab. 2018 Apr 25;31(5):485-95.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Lübbeke A, Rothman KJ, Garavaglia G, Barea C, Christofilopoulos P, Stern R, Hoffmeyer P. Strong association between smoking and the risk of revision in a cohort study of patients with metal-on-metal total hip arthroplasty. J Orthop Res. 2014 Jun;32(6):762-8. doi: 10.1002/jor.22603
Lubbeke A, Garavaglia G, Rothman KJ, Bonvin A, Roussos C, Miozzari H, Hoffmeyer P. Statins may reduce femoral osteolysis in patients with total hip arthroplasty. J Orthop Res. 2013 May 1;31(5):814-20.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
French M, Neighbors D, Carswell L, Williams R, Bush L. A model for estimating industry compliance costs of food labeling regulations. Agribusiness: An International Journal. 1993;8(2):165-86.